Cervical Cancer is the third largest female malignant tumor in the world and the second most common malignant tumor in Chinese women. According to estimates by the World Health Organization (WHO), there are more than 470,000 new cases of cervical cancer in the world each year, while China accounts for 28%. In the absence of appropriate and effective screening methods and preventive measures, the incidence of cervical cancer in Asia will increase by 40% by 2025.
Human papillomavirus (HPV) is the leading cause of cervical cancer. It is a very common virus. Up to 75% of women are infected with HPV at some stage of their lives. Most women can use their own immunity to put the virus. Clear; but if the HPV is persistently infected for a long time, the cervix is ​​in a state of repeated infection, and the cells often mutate and cause cancer. HPV persistent infection is the main cause of cervical cancer and its precancerous lesions, cervical intraepithelial neoplasia (CIN), and the more severe the cervical lesions, the higher the risk of high-risk HPV infection.
Fortunately, the cause of cervical cancer is clear and there is a long, reversible precancerous lesion in the development process. It is the only malignant tumor that can reduce morbidity and mortality through medical intervention. This means that cervical cancer is largely a preventable disease.
For decades, women have relied on cervical cytology (pap test) as a tool to detect the presence or absence of cervical cancer. However, with the development of medical technology, liquid-based thin layer cytology (TCT) and HPV gene detection have been developed in recent years for the screening of cervical cancer.
The global cervical cancer screening market will reach $22 billion by 2020
Recently, the latest research report released by the US market research institute Markets and Markets shows that the global cervical cancer screening market will reach 22 billion US dollars in 2020, which is worth 15 billion US dollars in 2014, during the forecast period (2015-2020). The compound annual growth rate (CAGR) is 7.0%.
The report pointed out that the growth of middle-aged and elderly female population, the high incidence of HPV infection, the rise of cervical cancer incidence, the increase of cervical cancer screening promotion, favorable government projects and financial support are the main factors driving the global cervical cancer screening market. factor. According to the report, the global cervical cancer screening market can be further divided according to the type of testing, end users, and geography.
—— According to the type of testing, the global cervical cancer screening market can be subdivided into Pap test, HPV test, combined test (co-test, cytology and high-risk HPV test), among which HPV/co-test It is expected to grow at a higher CAGR during the forecast period; this increase is largely due to the increased incidence of cervical cancer, higher consistency and reduced effectiveness of HPV and co-test results. Changes in annual treatment costs and regulatory regulations that are conducive to HPV testing.
—— According to the end user classification, the global cervical cancer screening market can be subdivided into hospitals, laboratories, independent doctor offices and clinics. In 2014, the laboratory occupied the largest market share; however, due to the growing capacity of hospital patients, the hospital segment will achieve faster growth during the forecast period.
-- By region, the global cervical cancer screening market can be subdivided into North America, Europe, Asia Pacific, and other countries (RoW). Among them, North America has the largest market share, followed by Europe. In the next five years, these two major markets are expected to grow in single digits, while the Asia Pacific region will grow at a higher rate during the forecast period, thanks to the huge investment opportunities in the region, market growth in this region. It will mainly be centered around China, India, Australia and the Middle East.
The report pointed out that the major players in the global cervical cancer screening and kit market include: Hologic (USA), Qiagen NV (Netherlands), Becton-Dickinson (USA), and Roche (Switzerland).
Source: Bio Valley
Jet Hydrant,Automatic Hydrant Water Cannon,Jet Fire Extinguishing System,Jet Hydrant Water Cannon
LIAONING YINGKOU TIANCHENG FIRE PROTECTION EQUIPMENT CO.,LTD , https://www.tcfiretech.com